Marrero J.A. Kulik L.M. Sirlin C.B. et al.

Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases.

Hepatology. 68: 723-750https://doi.org/10.1002/hep.29913Lope C.R. Tremosini S. Forner A. et al.

Management of HCC.

J Hepatol. 56https://doi.org/10.1016/s0168-8278(12)60009-9Nishikawa H. Kimura T. Kita R. et al.

Radiofrequency ablation for hepatocellular carcinoma.

Int J Hyperthermia. 29: 558-568https://doi.org/10.3109/02656736.2013.821528Therasse P. Arbuck S.G. Eisenhauer E.A. et al.

New guidelines to evaluate the response to treatment in solid tumors.

J Natl Cancer Inst. 92: 205-216Miller A. Hoogstraten B. Staquet M. et al.

Reporting results of cancer treatment.

Cancer. 47: 207-214Mora R.A. Ali R. Gabr A. et al.

Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma.

Abdom Radiol (NY). 43 (): 1723-1738https://doi.org/10.1007/s00261-017-1391-1Galun D. Basaric D. Zuvela M. et al.

Hepatocellular carcinoma: from clinical practice to evidence-based treatment protocols.

World J Hepatol. 7 (): 2274-2291https://doi.org/10.4254/wjh.v7.i20.2274

Multidisciplinary approach to HCC management: how can this be done?.

Dig Dis Sci. 64: 968-975https://doi.org/10.1007/s10620-019-05593-8

Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review.

J Gastroenterol Hepatol. 26: 1354-1360Mazzaferro V. Regalia E. Doci R. et al.

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

N Engl J Med. 334 (): 693-699https://doi.org/10.1056/NEJM199603143341104Byam J. Renz J. Millis J.M.

Liver transplantation for hepatocellular carcinoma.

Hepatobiliary Surg Nutr. 2: 22-30Kulik L.M. Fisher R.A. Rodrigo D.R. et al.

Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort.

Am J Transplant. 12 (): 2997-3007https://doi.org/10.1111/j.1600-6143.2012.04272.xLlovet J.M. Schwartz M. Mazzaferro V.

Resection and liver transplantation for hepatocellular carcinoma.

Semin Liver Dis. 25: 181-200Chen J. Huang K. Wu J. et al.

Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis.

Dig Dis Sci. 56 (): 1626-1633https://doi.org/10.1007/s10620-010-1482-0Mirnezami R. Mirnezami A.H. Chandrakumaran K. et al.

Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis.

HPB (Oxford). 13: 295-308https://doi.org/10.1111/j.1477-2574.2011.00295.xYao F.Y. Kerlan Jr., R.K. Hirose R. et al.

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Hepatology. 48 (): 819-827https://doi.org/10.1002/hep.22412Pomfret E.A. Washburn K. Wald C. et al.

Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.

Liver Transpl. 16 (): 262-278https://doi.org/10.1002/lt.21999Lurje I. Czigany Z. Bednarsch J. et al.

Treatment strategies for hepatocellular carcinoma - a multidisciplinary approach.

Int J Mol Sci. 20 (): 1465https://doi.org/10.3390/ijms20061465Freeman Jr., R.B. Steffick D.E. Guidinger M.K. et al.

Liver and intestine transplantation in the United States, 1997-2006.

Am J Transplant. 8 (): 958-976https://doi.org/10.1111/j.1600-6143.2008.02174.xBelghiti J. Kianmanesh R.

Surgical treatment of hepatocellular carcinoma.

HPB (Oxford). 7: 42-49https://doi.org/10.1080/13651820410024067Llovet J.M. Burroughs A. Bruix J.

Hepatocellular carcinoma.

Lancet. 362: 1907-1917https://doi.org/10.1016/s0140-6736(03)14964-1Kielar A. Fowler K.J. Lewis S. et al.

Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Abdom Radiol (NY). 43 (): 218-230https://doi.org/10.1007/s00261-017-1281-6Guan Y.S. Sun L. Zhou X.P. et al.

Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up.

World J Gastroenterol. 10: 3543-3548https://doi.org/10.3748/wjg.v10.i24.3543Shiina S. Tagawa K. Niwa Y. et al.

Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients.

AJR Am J Roentgenol. 160 (): 1023-1028https://doi.org/10.2214/ajr.160.5.7682378

Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma.

World J Gastroenterol. 19: 6127-6130Ahmed M. Solbiati L. Brace C.L. et al.International Working Group on Image-guided Tumor AblationInterventional Oncology Sans Frontières Expert PanelTechnology Assessment Committee of the Society of Interventional RadiologyStandard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe

Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update.

Radiology. 273 (): 241-260https://doi.org/10.1148/radiol.14132958Shiina S. Teratani T. Obi S. et al.

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Gastroenterology. 129 (): 122-130https://doi.org/10.1053/j.gastro.2005.04.009Luo W. Zhang Y. He G. et al.

Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis.

World J Surg Oncol. 15https://doi.org/10.1186/s12957-017-1196-2Bruix J. Reig M. Sherman M.

Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.

Gastroenterology. 150: 835-853https://doi.org/10.1053/j.gastro.2015.12.041Gaba R.C. Lewandowski R.J. Hickey R. et al.Society of Interventional Radiology Technology Assessment Committee

Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.

J Vasc Interv Radiol. 27 (): 457-473https://doi.org/10.1016/j.jvir.2015.12.752Tsochatzis E.A. Fatourou E. O'Beirne J. et al.

Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.

World J Gastroenterol. 20: 3069-3077https://doi.org/10.3748/wjg.v20.i12.3069Lammer J. Malagari K. Vogl T. et al.PRECISION V Investigators

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Cardiovasc Intervent Radiol. 33 (): 41-52https://doi.org/10.1007/s00270-009-9711-7Meza-Junco J. Montano-Loza A.J. Liu D.M. et al.

Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?.

Cancer Treat Rev. 38 (): 54-62https://doi.org/10.1016/j.ctrv.2011.05.002

Current concepts in transarterial chemoembolization of hepatocellular carcinoma.

Abdom Imaging. 36: 677-683Piscaglia F. Ogasawara S.

Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment.

Liver Cancer. 7: 104-119Hickey R.M. Lewandowski R.J. Salem R.

Yttrium-90 radioembolization for hepatocellular carcinoma.

Semin Nucl Med. 46: 105-108Lau W.Y. Sangro B. Chen P.J. et al.

Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.

Oncology. 84 (): 311-318https://doi.org/10.1159/000348325Iñarrairaegui M. Thurston K.G. Bilbao J.I. et al.

Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.

J Vasc Interv Radiol. 21 (): 1205-1212https://doi.org/10.1016/j.jvir.2010.04.012Jiang W. Lu Z. He Y. et al.

Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.

Clin Cancer Res. 3 (): 395-399Abou-Alfa G.K. Schwartz L. Ricci S. et al.

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol.

. 24 (): 4293-4300https://doi.org/10.1200/JCO.2005.01.3441Llovet J.M. Montal R. Sia D. et al.

Molecular therapies and precision medicine for hepatocellular carcinoma.

Nat Rev Clin Oncol. 15: 599-616https://doi.org/10.1038/s41571-018-0073-4

Liver resection and surgical strategies for management of primary liver cancer.

Cancer Control. 25 ()Cherqui D. Laurent A. Mocellin N. et al.

Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.

Ann Surg. 250 (): 738-746https://doi.org/10.1097/SLA.0b013e3181bd582bTheysohn J.M. Ertle J. Müller S. et al.

Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma.

Clin Radiol. 69 (): 172-178https://doi.org/10.1016/j.crad.2013.09.009Garlipp B. de Baere T. Damm R. et al.

Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization.

Hepatology. 59 (): 1864-1873https://doi.org/10.1002/hep.26947Morimoto M. Numata K. Kondou M. et al.

Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization.

Cancer. 116 (): 5452-5460https://doi.org/10.1002/cncr.25314American College of Radiology

Liver Imaging Reporting and Data System version 2018 Manual.

() ()Voizard N. Cerny M. Assad A. et al.

Assessment of hepatocellular carcinoma treatment response with LI-RADS: A pictorial review.

Insights Imaging. 10https://doi.org/10.1186/s13244-019-0801-zCrocetti L. Della Pina C. Cioni D. et al.

Peri-intraprocedural imaging: US, CT, and MRI.

Abdom Radiol (NY). 36: 648-660https://doi.org/10.1007/s00261-011-9750-9Ibrahim S.M. Nikolaidis P. Miller F.H. et al.

Radiologic findings following Y90 radioembolization for primary liver malignancies.

Abdom Imaging. 34 (): 566-581https://doi.org/10.1007/s00261-008-9454-yKallini J.R. Miller F.H. Gabr A. et al.

Hepatic imaging following intra-arterial embolotherapy.

Abdom Radiol (NY). 41: 600-616https://doi.org/10.1007/s00261-016-0639-5Mendiratta-Lala M. Gu E. Owen D. et al.

Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy.

Int J Radiat Oncol Biol Phys. 102 (): 1063-1069https://doi.org/10.1016/j.ijrobp.2017.08.022Mendiratta-Lala M. Masch W. Owen D. Aslam A. et al.

Natural history of hepatocellular carcinoma after stereotactic body radiation therapy.

Abdom Radiol (NY). https://doi.org/10.1007/s00261-020-02532-4

Imaging of the liver following interventional therapy for hepatic neoplasms.

Radiol Clin North Am. 53: 1061-1076https://doi.org/10.1016/j.rcl.2015.05.009Kim K.W. Lee J.M. Choi B.I.

Assessment of the treatment response of HCC.

Abdom Imaging. 36: 300-314

Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI.

World J Gastroenterol. 20: 4160https://doi.org/10.3748/wjg.v20.i15.4160Ehman E.C. Umetsu S.E. Ohliger M.A. et al.

Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy.

Abdom Radiol (NY). 41: 2161-2168https://doi.org/10.1007/s00261-016-0837-1Hussein R.S. Tantawy W. Abbas Y.A.

MRI assessment of hepatocellular carcinoma after locoregional therapy.

Insights Imaging. 10https://doi.org/10.1186/s13244-019-0690-1Mendiratta-Lala M. Brook O.R. Midkiff B.D. et al.

Quality initiatives: strategies for anticipating and reducing complications and treatment failures in hepatic radiofrequency ablation.

RadioGraphics. 30: 1107-1122https://doi.org/10.1148/rg.304095202

Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma.

World J Gastroenterol. 9: 2686https://doi.org/10.3748/wjg.v9.i12.2686

Surgical and locoregional therapy of HCC: TACE.

Liver Cancer. 4: 165-175https://doi.org/10.1159/000367739Gerum S. Heinz C. Belka C. et al.

Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease.

Radiation Oncol. 13https://doi.org/10.1186/s13014-018-1048-4

Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines.

Radiat Oncol J. 34: 160-167https://doi.org/10.3857/roj.2016.01970Lee S. Kim H. Ji Y. et al.

Evaluation of hepatic toxicity after repeated stereotactic body radiation therapy for recurrent hepatocellular carcinoma using deformable image registration.

Sci Rep. 8https://doi.org/10.1038/s41598-018-34676-1Gordic S. Corcuera-Solano I. Stueck A. et al.

Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology.

J Hepatol. 67: 1213-1221https://doi.org/10.1016/j.jhep.2017.07.030Bruix J. Sherman M. Llovet J.M. et al.

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference.

J Hepatol. 35: 421-430https://doi.org/10.1016/s0168-8278(01)00130-1

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Semin Liver Dis. 30: 052-060https://doi.org/10.1055/s-0030-1247132Elsayes K.M. Kielar A.Z. Chernyak V. et al.

LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.

J Hepatocell Carcinoma. 6 (): 49-69https://doi.org/10.2147/JHC.S186239Tang A. Singal A.G. Mitchell D.G. et al.

Introduction to the liver imaging reporting and data system for hepatocellular carcinoma.

Clin Gastroenterol Hepatol. 17 (): 1228-1238https://doi.org/10.1016/j.cgh.2018.10.014Shropshire E.L. Chaudhry M. Miller C.M. et al.

LI-RADS treatment response algorithm: performance and diagnostic accuracy.

Radiology. 292: 226-234https://doi.org/10.1148/radiol.2019182135Chaudhry M. Mcginty K.A. Mervak B. et al.

The LI-RADS Version 2018 MRI treatment response algorithm: evaluation of ablated hepatocellular carcinoma.

Radiology. 294: 320-326https://doi.org/10.1148/radiol.2019191581Cools K.S. Moon A.M. Burke L.M. et al.

Validation of the liver imaging reporting and data system treatment response criteria after thermal ablation for hepatocellular carcinoma.

Liver Transpl. 26: 203-214https://doi.org/10.1002/lt.25673Zhang Y. Wang J. Li H. et al.

Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.

Ann Transl Med. 8: 388https://doi.org/10.21037/atm.2020.03.120Chung W. Lee K. Park M. et al.

Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study.

Am J Roentgenol. 199: 349-359https://doi.org/10.2214/ajr.11.7563Hunt S.J. Yu W. Weintraub J. et al.

Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation.

J Vasc Interv Radiol. 20: 30-38https://doi.org/10.1016/j.jvir.2008.09.034Abdel Razek A. El-Serougy L. Saleh G. et al.

Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.

Diagn Interv Imaging. https://doi.org/10.1016/j.diii.2020.03.008Kim S.W. Joo I. Kim H. et al.

LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.

Eur Radiol. 30: 2861-2870https://doi.org/10.1007/s00330-019-06623-9Park S. Joo I. Lee D.H. et al.

Diagnostic performance of LI-RADS treatment response algorithm for hepatocellular carcinoma: adding ancillary features to MRI compared with enhancement patterns at CT and MRI.

Radiology. : 192797https://doi.org/10.1148/radiol.2020192797Do R.K. Mendiratta-Lala M.

Moving away from uncertainty: a potential role for ancillary features in LI-RADS treatment response.

Radiology. : 202637https://doi.org/10.1148/radiol.2020202637